/Bristol-Myers%20Squibb%20Co_%20logo%20on%20building-by%20tatu%20Campelo%20via%20iStock.jpg)
Bristol-Myers Squibb Company (BMY) is one of the leading biopharmaceutical companies focused on developing treatments for cancer, inflammatory, immunologic, cardiovascular and fibrotic diseases. With a market cap of $119.8 billion, Bristol-Myers’ operations span various countries in the Americas, Europe, and the Indo-Pacific.
The Princeton, New Jersey-based pharma giant has slightly lagged behind the S&P 500 over the past year. BMY has gained 19.7% over the past 52 weeks, compared to the S&P 500 Index’s ($SPX) 23.3% surge during the same time frame. However, BMY has soared 4.6% on a YTD basis outpacing SPX’s 2.6% gains in 2025.
Narrowing the focus, Bristol-Myers has significantly outperformed the industry-focused First Trust Nasdaq Pharmaceuticals ETF’s (FTXH) 2.3% gains over the past 52 weeks and 3.4% returns on a YTD basis.
Bristol-Myers Squibb’s stock prices soared 5.9% after the release of its impressive Q3 results on Oct. 31. Driven by the increase in sales of its Growth Portfolio and Eliquis, BMY’s total revenues surged 8.4% year-over-year to $11.9 billion which surpassed the Street’s expectations by over 5%. Although its adjusted net earnings declined 11.8% year-over-year to approximately $3.7 billion, its adjusted EPS of $1.80 surpassed the consensus estimates by a staggering 20.8%.
BMY is set to announce its fiscal 2024 results in the upcoming week and analysts are anticipating a major 87.8% year-over-year decline in earnings to $0.92 per share. However, the company has a robust earnings surprise history and has surpassed the Street’s bottom-line estimates in each of the past four quarters.
Among the 25 analysts covering the BMY stock, the consensus rating is “Moderate Buy.” That’s based on seven “Strong Buy” ratings, 17 “Hold,” and one “Strong Sell.”
This configuration is notably more bullish than two months ago when the stock had a consensus “Hold” rating, and only six analysts gave “Strong Buy” ratings.
On Jan. 8, Truist Securities analyst Robyn Karnauskas maintained a “Buy” rating while raising the price target to $65, which indicates a 9.9% premium to current price levels.
BMY’s mean price target of $60.09 represents a modest 1.6% premium to current price levels, while its street-high target of $73 indicates a staggering 23.4% upside potential.
